58 pages
- GLP-1 Dose SchedulerGenerate week-by-week dose escalation schedules for semaglutide, tirzepatide, and retatrutide.
- Best Peptides for Women Over 40: Menopause, Fat Loss, Sleep & SkinEvidence-based guide to peptides for women over 40 - menopause weight gain, sleep disruption, skin aging, libido, and which peptides address each.Updated Mar 23, 2026
- Telehealth Providers Compared (2026): GLP-1, TRT, HRT, Prices & ScoresInteractive provider × service comparison: effective monthly cost, upfront price, labs, LegitScript and Trustpilot, scored on a public rubric you can re-weight.
- GLP-1 Cost (2026): Wegovy $149–$349, Zepbound $299–$449, Medicare $50What a GLP-1 really costs: Medicare Bridge $50/mo, savings cards from $25, brand-name self-pay via TrumpRx/LillyDirect/NovoCare, and compounded tirzepatide ($1,788–$4,668/yr) last.
- Compounded GLP-1 Providers Compared (2026): Real Monthly Cost, Medals & OffersMEDGm, HealthRX, Found, Gala and Luvo side by side: effective monthly cost for tirzepatide and semaglutide, what you pay to start, labs, first-month offers.
- GLP-1 With Insurance or Medicare (2026): $25 Savings Cards, $50 Medicare GLP-1 BridgeHow to pay the least for Wegovy, Zepbound or Foundayo with coverage: savings cards from $25/mo with commercial insurance, the Medicare GLP-1 Bridge at $50/mo (Jul 1, 2026–Dec 31…
- Foundayo vs Wegovy Pill (2026): Both $149 to Start, $3,188 vs $3,338 Year OneFoundayo (orforglipron) vs the Wegovy pill (oral semaglutide): self-pay prices dose by dose ($149 to start, $299 at maintenance), year-one cost, food rules, trial results, and…
- GLP-1 Dose Escalation Guide: Semaglutide, Tirzepatide & RetatrutideComprehensive guide to GLP-1 agonist dosing schedules for semaglutide (Wegovy/Ozempic), tirzepatide (Mounjaro/Zepbound), and retatrutide with syringe unit calculations and…Updated Mar 22, 2026
- Semaglutide Dose Calculator: How to Measure Your Weekly InjectionCalculate semaglutide doses in insulin syringe units and understand the Wegovy and Ozempic dose escalation schedules.Updated Mar 22, 2026
- Tirzepatide vs Semaglutide: Dosing, Efficacy and Half-Life ComparedSide-by-side comparison of tirzepatide and semaglutide covering mechanisms, half-lives, dose schedules, and clinical weight loss data.Updated Mar 22, 2026
- Retatrutide: The Triple Agonist GLP-1 Peptide - Dosing and PK GuideComprehensive guide to retatrutide covering its triple agonist mechanism, 6-day half-life, and Phase II dose escalation.Updated Mar 22, 2026
- Compounded Semaglutide vs Wegovy vs Rybelsus: Cost, Bioavailability, and Dosing ComparedSide-by-side comparison of compounded injectable semaglutide, branded Wegovy/Ozempic pens, and oral Rybelsus - covering cost, bioavailability, dose calculation, and 2026 FDA…Updated Mar 22, 2026
- Retatrutide Phase 3 TRIUMPH Trial Update 2026: Weight Loss Data, Timeline & AccessComplete Phase 3 TRIUMPH trial update for retatrutide (LY3437943): weight loss results, comparison with tirzepatide, FDA approval timeline, and compounded access in 2026.Updated Mar 22, 2026
- Semaglutide vs Tirzepatide vs Retatrutide: The Complete GLP-1 Triple ComparisonSingle, dual, and triple agonist GLP-1 peptides compared head-to-head.Updated Mar 22, 2026
- Semaglutide Compounding vs Brand: What the FDA Shortage Rules Mean for YouCompounded semaglutide costs 80% less than Wegovy.Updated Mar 22, 2026
- Tesofensine Dosage Guide: The Non-GLP-1 Fat Loss CompoundTesofensine dosage guide - triple monoamine reuptake inhibitor mechanism, 10.6% weight loss data, comparison to GLP-1 peptides.Updated Mar 23, 2026
- CagriSema Explained: Novo Nordisk's Semaglutide + Cagrilintide CombinationCagriSema combines semaglutide + cagrilintide (amylin analog) for 23% weight loss.Updated Mar 23, 2026
- Orforglipron: The First Oral Non-Peptide GLP-1 - Mechanism, Trials & TimelineOrforglipron is Eli Lilly's oral non-peptide GLP-1 RA.Updated Mar 23, 2026
- Survodutide Deep Dive: The GLP-1/Glucagon Dual Agonist for ObesitySurvodutide mechanism, Phase 2/3 trial results, receptor comparison vs semaglutide and tirzepatide, and future availability.Updated Mar 23, 2026
- High-Dose Oral Semaglutide & Wegovy 25 mg: What You Need to KnowOral semaglutide 25-50 mg daily vs injectable Wegovy 2.4 mg/week - bioavailability, dose escalation, trial data, and compounding.Updated Mar 23, 2026
- Tirzepatide Titration: How to Break Through a Weight Loss StallHitting a plateau on Mounjaro or Zepbound?Updated Apr 6, 2026
- GLP-1 Muscle Loss: How to Protect Lean Mass During Weight LossHow much of the weight lost on semaglutide or tirzepatide is lean mass, what the DXA substudies show, and how protein and resistance training help protect muscle.Updated Oct 8, 2026
- GLP-1 Microdosing: Maintenance Protocols Post-Weight LossWhat happens when you reach your goal weight?Updated Sep 21, 2026
- Pemvidutide (Altimmune): The GLP-1/Glucagon Agonist that Preserves MuscleDeep dive into Pemvidutide (ALT-801), the dual agonist demonstrating massive fat reduction with unprecedented preservation of lean muscle mass in Phase 2 MOMENTUM trials.Updated Sep 21, 2026
- Mazdutide: The GLP-1/Glucagon Dual Agonist Efficacy Trial BreakdownAnalyzing Mazdutide, the clinical-stage dual agonist.Updated Sep 21, 2026
- GLP-1 Muscle Loss: Can Growth Factors and Peptides Prevent Sarcopenia?Up to 40% of weight lost on GLP-1 agonists is lean mass.Updated Apr 7, 2026
- AOD-9604 vs Tirzepatide: Modern Fat Loss Peptides ComparedAOD-9604 (the "lipolysis fragment" of hGH) versus tirzepatide (dual GLP-1/GIP agonist) - mechanisms, clinical evidence, side effects, cost, and which approach suits different…Updated Apr 7, 2026
- Retatrutide & CagriSema: The Next Evolution Beyond TirzepatideA deep dive into the clinical trials of triple-agonists and amylin analogs shaping the future of metabolic medicine.Updated Apr 14, 2026
- Stopping Semaglutide: What the Trials Show About Weight RegainWhat the STEP 1 extension and STEP 4 trials found after semaglutide was stopped, what is not known about tapering, and questions to ask your prescriber.Updated Oct 8, 2026
- The Tirzepatide + AOD-9604 Synergy: Can You Stack GLP-1s with Lipolytic Peptides?Examining the theoretical and applied science of combining dual-agonists with specific lipolytic fragments to break stubborn plateaus.Updated Apr 24, 2026
- Survodutide & Mazdutide: Tracking the Future of GLP-1 Clinical Trials in 2026A comprehensive overview of the Glucagon/GLP-1 co-agonists currently making headlines in Phase 3 obesity and liver fat clinical trials.Updated Apr 28, 2026
- Retatrutide vs Tirzepatide: The Next Evolution of GLP-1 Weight LossA head-to-head analysis of Tirzepatide (dual GIP/GLP-1) versus Retatrutide (triple GIP/GLP-1/Glucagon), examining Phase 3 clinical data, metabolic rates, and dosing.Updated Apr 18, 2026
- Stacking Semaglutide + BPC-157 to Mitigate GLP-1 GI Side EffectsHow deploying the gut-healing peptide BPC-157 alongside Semaglutide can clinically eliminate nausea, repair gut lining, and improve GLP-1 compliance rates.Updated Apr 18, 2026
- Tirzepatide + Tesofensine: The Ultimate Fat Loss StackExploring the synergistic mechanisms of combining the GLP-1/GIP agonist Tirzepatide with the triple monoamine reuptake inhibitor Tesofensine for extreme fat oxidation.Updated Apr 18, 2026
- MariTide Explained: Amgen’s Monthly GIPR-Antagonist / GLP-1 Obesity ProgramMariTide (maridebart cafraglutide / AMG 133) explained: mechanism vs semaglutide, tirzepatide, and retatrutide, Phase 2 trial status from opened sources, and why it is not a…Updated Sep 21, 2026
- GLP-1 Side Effects: What the FDA Labels SayStomach side effects dominate.Updated Oct 8, 2026
- Peptide Beginner Guide 2026: Which Peptide Should You Start With?The complete beginner guide to peptides - how to choose your first peptide, what equipment you need, how to reconstitute, inject safely, verify purity, and use Kymata Health free…Updated Mar 22, 2026
- Peptides and Intermittent Fasting: Timing, Absorption & Protocol GuideHow to optimize peptide dosing around fasting windows - GLP-1s, BPC-157, ipamorelin timing strategies and absorption science.Updated Mar 23, 2026
- SemaglutideOnce-weekly GLP-1 receptor agonist.
- TirzepatideDual GIP/GLP-1 agonist.
- RetatrutideLilly triple GLP-1/GIP/glucagon analog (LY3437943).
- LiraglutideOnce-daily GLP-1 RA.
- CagrilintideLong-acting amylin analog, not a GLP-1.
- CagriSemaNovo co-formulation: cagrilintide 2.4 mg plus semaglutide 2.4 mg in the trials.
- DulaglutideOnce-weekly GLP-1 RA fused to IgG4 Fc (Trulicity).
- ExenatideFirst-in-class GLP-1 RA (Byetta BID / Bydureon weekly).
- LixisenatideOnce-daily short-acting GLP-1 RA (Adlyxin / Lyxumia), often with glargine as Soliqua.
- MazdutideInnovent GLP-1/glucagon dual agonist (IBI362).
- OrforglipronLilly oral small-molecule GLP-1R agonist (LY3502970), not a peptide and not Rybelsus.
- PemvidutideAltimmune GLP-1/glucagon dual agonist (ALT-801).
- PramlintideMealtime amylin analog (Symlin), adjunct to insulin.
- SurvodutideBoehringer/Zealand GLP-1/glucagon dual agonist (BI 456906).
- MariTideAmgen investigational antibody-peptide conjugate (AMG 133 / MariTide): GIP receptor antagonist plus GLP-1 receptor agonism, studied on a monthly-class schedule in obesity programs.
- AmycretinNovo Nordisk investigational dual amylin and GLP-1 receptor agonist (amycretin), studied in oral and injectable obesity programs.
- VK2735Viking Therapeutics investigational dual GLP-1/GIP receptor agonist (VK2735), studied in subcutaneous and oral obesity programs.
- PetrelintideZealand Pharma investigational long-acting amylin receptor agonist (petrelintide / ZP8396).
- EloralintideEli Lilly investigational long-acting amylin receptor agonist (eloralintide / LY3841136).
- TesofensineOral triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin) studied for obesity.
